During the past decade, Yamagata University Hospital conducted 46 clinical trials. In the 10-year time frame, 46 clinical trials started and 12 clinical trials were completed, i.e. on average, 26.1% percent of trials that started reached the finish line to date. In the past 5 years, 28 clinical trials started and 10 clinical trials were completed. i.e. 35.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Yamagata University Hospital" #1 sponsor was "Pfizer" with 17 trials, followed by "Gilead Sciences" with 5 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored, "Celgene" with 3 trials sponsored and "Otsuka Pharmaceutical Co., Ltd." with 3 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Yamagata University Hospital" #1 collaborator was "Astellas Pharma Inc" with 2 trials as a collaborator, "Tokyo Medical and Dental University" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "EPS Corporation" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Yamagata University Hospital" are "Multiple Myeloma" (5 trials), "Nonalcoholic Steatohepatitis" (4 trials), "Acute Myeloid Leukemia" (3 trials), "Carcinoma, Renal Cell" (2 trials) and "Colorectal Cancer" (2 trials). Many other conditions were trialed in "Yamagata University Hospital" in a lesser frequency.

Most popular intervention types in "Yamagata University Hospital" are "Drug" (50 trials), "Biological" (6 trials), "Other" (2 trials), "Procedure" (2 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Elranatamab" (3 trials), "Rituximab" (3 trials), "Axitinib (AG-013736)" (2 trials) and "Azacitidine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Yamagata University Hospital" are 54 trials for "All" genders, 3 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Yamagata University Hospital". undefined are not yet recruiting, 17 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Yamagata University Hospital, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Yamagata University Hospital, 5 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".